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Pancreatic ductal adenocarcinoma (PDAC) is among the most fatal of malignan-
cies with an extremely poor prognosis. The objectives of this study were to pro-
vide a detailed understanding of PDAC pathophysiology in view of the host
immune response. We examined the PDAC tissues, sera, and peripheral blood
cells of PDAC patients using immunohistochemical staining, the measurement of
cytokine ⁄ chemokine concentrations, gene expression analysis, and flow cytome-
try. The PDAC tissues were infiltrated by macrophages, especially CD33+CD163+
M2 macrophages and CD4+ T cells that concomitantly express programmed cell
death-1 (PD-1). Concentrations of interleukin (IL)-6, IL-7, IL-15, monocyte chemo-
tactic protein-1, and interferon-c-inducible protein-1 in the sera of PDAC patients
were significantly elevated. The gene expression profile of CD14+ monocytes and
CD4+ T cells was discernible between PDAC patients and healthy volunteers, and
the differentially expressed genes were related to activated inflammation.
Intriguingly, PD-1 was significantly upregulated in the peripheral blood CD4+
T cells of PDAC patients. Correspondingly, the frequency of CD4+PD-1+ T cells
was increased in the peripheral blood cells of PDAC patients, and this increase
correlated to chemotherapy resistance. In conclusion, inflammatory conditions in
both PDAC tissue and peripheral blood cells in PDAC patients were prominent,
highlighting monocytes ⁄macrophages as well as CD4+ T cells with influence of
the clinical prognosis.
P ancreatic ductal adenocarcinoma (PDAC) is one of themost fatal solid malignancies with a 5-year survival rate
of <5% and a median survival of 4–6 months in Japan as well
as in other countries.(1,2) Surgical resection is the only method
for achieving radical treatment; however, only 15–20% of
patients are diagnosed in the operable early stage.(3) For unre-
sectable PDAC, gemcitabine-based chemotherapeutic regimens
are efficacious; however, improvements in survival are limited
to only several months, and no complete remission is funda-
mentally expected.(4) Therefore, it is extremely important to
understand the pathophysiology of PDAC in order to establish
novel diagnostic methods for early detection as well as to
develop novel effective therapies.
Cancer is frequently associated with inflammation induced
by the host immune system,(5) involving a variety of
immune-mediating cells, including the Th1 helper T cells
and cytotoxic T lymphocytes,(6) which inhibit cancer progres-
sion, and the myeloid-derived suppressor cells(7) and regula-
tory T cells,(8) which are cancer-promoting inflammatory
cells. These anticancer and cancer-promoting immune-mediat-
ing cells have a complex involvement in the persistent
inflammation associated with cancer that influences the
patient’s prognosis. Some inflammatory cells such as regula-
tory T cells, myeloid-derived suppressor cells, as well as
humoral mediator interleukin (IL)-6, are reported to be
involved in PDAC;(9) however, details of the systemic
inflammatory condition of PDAC has not been sufficiently
studied. Accordingly, the purpose of this study was to eluci-
date the systemic inflammatory state of PDAC by investigat-
ing the inflammatory markers in the local cancer tissue,
serum, and peripheral blood.
Materials and Methods
Patients and pancreatic ductal adenocarcinoma tissues. Twenty
specimens that were surgically removed from PDAC patients
(Table 1) were used for pathological analysis. Both PDAC
patients and healthy volunteers were enrolled after providing
informed consent prior to the serum concentration analysis of
cytokines and chemokines, gene expression analysis of periph-
eral blood cells, and flow cytometry analysis. The clinical
characteristics of the study participants are provided in Tables
S1–S3. The clinical stages were evaluated in accordance with
the TNM staging system for pancreatic carcinoma issued by
the Union of International Cancer Control (7th edition). The
therapeutic effect of chemotherapy was assessed in terms of
partial responsiveness, stable disease, and progressive disease
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in accordance with the Response Evaluation Criteria in Solid
Tumors. The study was approved by the institutional review
board and was carried out in accordance with the Declaration
of Helsinki.
Isolation of peripheral blood mononuclear cells. Peripheral
blood was obtained prior to any treatments for PDAC. Periph-
eral blood mononuclear cells (PBMCs) were isolated from
heparinized venous blood using Ficoll–Hypaque density gradi-
ent centrifugation (Sigma-Aldrich, St. Louis, MO, USA), as
previously described.(10) The obtained fraction of PBMCs was
incubated with bead-labeled anti-CD4, anti-CD8, anti-CD14,
or anti-CD15 antibodies (Miltenyi, Cologne, Germany), fol-
lowed by isolation using a magnet.
Additional procedures. Additional materials and methods are
presented in Data S1.
Results
Features of local immune-mediating cells in PDAC tissues. To
elucidate local inflammatory conditions of PDAC, we immuno-
histochemically analyzed the surgically resected PDAC tissues.
We found that CD33+ myeloid cells markedly infiltrated
PDAC tissues (Fig. 1a,b, Table 1). Neutrophil elastase-positive
cells were rarely observed among CD33+ cells (Fig. 1c), sug-
gesting that CD33+ myeloid-lineage cells were likely mono-
cytes ⁄macrophages. There was a fraction of CD14+ cells
(Fig. 1d,e, Table 1) and a more prominent fraction of CD163+
monocytes ⁄macrophages among CD33+ cells (Fig. 1f,g,
Table 1), indicating infiltration of M2 suppressive macrophag-
es. Lymphoid follicles were observed adjacent to PDAC tis-
sues, where most of the infiltrating lymphocytes were CD3+
T cells (Fig. 1h). Among infiltrating CD3+ T cells, CD4+
T cells were predominant compared to the CD8+ T cells
(Fig. 1i,j). T-bet+ cells were not frequently observed (Fig. 1k),
whereas FoxP3+ cells as well as programmed cell death-1
(PD-1)+ cells were more frequently observed (Fig. 1l,m,
Table 1), suggesting that regulatory or activated CD4+ T cells
had infiltrated the PDAC tissues.
Serum cytokine and chemokine concentration in PDAC patients.
We next assessed concentration level of panels of cytokines
and chemokines in sera of PDAC patients (Table S1). Serum
concentrations of the cytokines IL-6, IL-7, and IL-15 were sig-
nificantly elevated in PDAC patients compared to healthy vol-
unteers (Fig. 2). Among chemokines, monocyte chemotactic
protein-1 (MCP-1) and interferon-c-inducible protein-10 (IP-
10) were significantly elevated, and IL-8 was relatively high in
PDAC patients, although this was not statistically significant
(P = 0.06; Fig. 2). We used real time detection-PCR (RTD-
PCR) to measure the expression levels of mRNAs encoding
these cytokines and chemokines in CD14+ monocytes ⁄macro-
phages and CD4+ T cells of PDAC patients. We found that
IL-15 expression by CD14+ monocytes ⁄macrophages and IL-6
and IL-7 expression by CD4+ T cells of PDAC patients were
significantly upregulated compared to those of healthy volun-
teers (Fig. S1), suggesting that peripheral CD14+ monocytes
⁄macrophages and CD4+ T cells contribute to the elevations in
cytokine levels evident in the sera of PDAC patients. Such
cells are the local macrophages and CD4+ T cells associated
with inflammation of PDAC tissues.
Distinct gene expression profile of CD14+ monocytes and CD4+
T cells in PBMCs of patients with PDAC. Local infiltrating
inflammatory cells and serum cytokine ⁄ chemokine elevation
highlighted macrophages and CD4+ T cells in the context of
PDAC inflammation. We further examined whether peripheral
blood cells were affected using gene expression analysis with
DNA microarray. Unsupervised clustering analysis of gene
expression showed a clear gene expression pattern for all
blood cells (Fig. 3a), which was consistent with our previous
report.(11) The analysis of peripheral blood cell subfractions
in PDAC patients showed a discernible gene expression
Table 1. Inflammatory features of pancreatic ductal adenocarcinoma tissues and clinical characteristics of patients
Patient no. Age, years Sex Stage Tumor size, mm Degree of inflammation
Infiltrating inflammatory cells†
CD4 T-bet FoxP3 PD-1 CD33 CD14 CD163
1 71 F II 25 Mild >100 <5 24 6 >100 78 >100
2 57 M III 25 Moderate 58 <5 35 14 33 73 >100
3 61 F II 15 Severe 48 <5 39 26 >100 >100 >100
4 54 F III 55 Mild >100 <5 27 <5 >100 12 56
5 70 F IV 33 Mild 46 <5 12 45 >100 38 >100
6 66 M II 25 Moderate 26 <5 16 15 >100 85 >100
7 60 F III 18 Moderate >100 <5 37 6 >100 62 >100
8 78 M III 37 Moderate >100 <5 48 8 >100 28 65
9 77 M II 30 Moderate 55 39 26 18 >100 54 >100
10 57 M III 55 Moderate 71 <5 13 57 >100 <10 98
11 65 M III 43 Moderate >100 12 51 6 >100 >100 >100
12 68 F III 25 Severe >100 <5 22 12 >100 >100 >100
13 62 M II 22 Mild >100 <5 <10 7 >100 19 59
14 65 M II 25 Moderate >100 5 <10 32 >100 23 73
15 59 F II 18 Mild >100 <5 <10 <5 >100 43 92
16 66 M I 10 Moderate >100 13 74 58 >100 <10 <10
17 70 M III 5 Moderate >100 <5 14 <5 >100 >100 41
18 57 F II 18 Moderate >100 <5 15 <5 >100 24 >100
19 63 M II 25 Mild >100 <5 23 <5 >100 27 83
20 64 F II 21 Moderate >100 23 51 42 >100 >100 >100
†The number of each inflammatory cells was assessed per high power field. F, female; M, male.
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profile of the CD14+ monocyte and CD4+T cell fractions
(Fig. 3b,c), whereas CD8+ and CD15+ cell fractions did not
(Fig. 3d,e).
Unsupervised analysis of the gene expression profile in iso-
lated CD14+ monocytes and CD4+ T cells in a larger cohort
(Table S3) also showed relatively discernible clusters for
PDAC patients and healthy volunteers (Fig. 4a,c). Signifi-
cantly altered gene expression by ≥1.5-fold in peripheral
CD14+ monocytes of PDAC patients compared to healthy
volunteers was observed in 261, 126, and 85 genes at P-val-
ues of <0.05, <0.01, and <0.005, respectively. Most of these
genes were upregulated (177 ⁄261, 87 ⁄126, and 61 ⁄85,
respectively). The numbers of significantly altered genes by
≥1.5-fold in CD4+ cells were 690, 496, and 419 with P-val-
ues of <0.05, <0.01, and <0.005, respectively. Most of these
were also upregulated (459 ⁄690, 349 ⁄496, and 298 ⁄ 419,
respectively). Unsupervised analysis of the gene expression
profile using the 261 significantly altered genes from CD14+
monocytes and 496 genes from CD4+ T cells showed dis-
tinct clusters for PDAC patients and healthy volunteers
(Fig. 4b,d).
The biological process networks related to the 261 genes,
whose expression was significantly altered ≥1.5-fold in CD14+
monocytes ⁄macrophages of PDAC patients, included the cell
cycle, inflammation, blood coagulation, cell adhesion, and
development (Table 2). We randomly selected 17 genes from
the list of those 50 most significantly upregulated upon micro-
array analysis (Table 3), and measured transcriptional expres-
sion levels by RTD-PCR. We found that most of these genes
were indeed upregulated, including the adhesion-related gene
CD226 and the cell cycle-related gene CDK6 (Table S4). Bio-





Fig. 1. Immunohistochemical analysis of pancreatic ductal adenocarcinoma (PDAC) tissues. Surgically resected PDAC tissues were immunohisto-
chemically stained. (a, b) CD33: several positive cells were scattered in the fibroadipose area around PDAC, which were mainly composed of a
monocyte (arrows in b) and macrophage (arrowheads in b) morphology. (c) Neutrophil elastase: a few positive cells were observed. (d, e) CD14:
several positive cells highlighting the monocyte morphology. (f, g) Double immunostaining of CD163 (brown) and CD33 (green). Most of the
CD163+ cells were also positive for CD33. (h) CD3: lymphoid aggregation around PDAC was mainly composed of CD3+ T cells. (i) CD4: the major-
ity of lymphoid aggregation was CD4+ T cells. (j) CD8: the number of CD8+ cells was small compared to that of CD4+ cells shown in (i). (k) Dou-
ble immunostaining of T-bet (brown, nuclear expression) and CD4 (green). Double-positive cells were observed (arrows), but the number was
very small. (l) Double immunostaining of FoxP3 (brown, nuclear expression) and CD4 (green). Several double-positive cells were scattered
(arrows). (m) PD-1 (brown) and CD4 (green): several double-positive cells were found (arrows). Magnification: a, c, d, f, h, i, and j, 940; b, e, g,
k, l, and m, 9100.
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expression was significantly altered ≥1.5-fold in CD4+ T cells
of PDAC patients mostly included the cell cycle and inflam-
mation as well as DNA damage and apoptosis (Table 4). We
randomly selected 18 genes from the list of those 50 most
significantly upregulated, as revealed by microarray analysis
(Table 5), and measured transcriptional expression levels using
RTD-PCR. We found that most of these genes were indeed up-
regulated, including the cell cycle-associated gene PTTG1 and
the apoptosis-related gene BAX (Table S4). Interestingly, PD-
1, which is expressed on the activated T cell to attenuate the T
cell receptor signaling pathway, was also included (Table 5).
Thus, CD14+ monocytes and CD4+T cells were the meaning-
fully affected subpopulations of peripheral blood cells in
PDAC patients.
Increased frequency of CD4+PD-1+ subpopulation in PBMCs of
PDAC patients. CD4+PD-1+ cells infiltrated local PDAC tis-
sues, and PD-1 gene expression was significantly up-regulated
in CD4+ T cells of peripheral blood of PDAC patients, we fur-
ther examined the frequency of PD-1-expressing cells in
peripheral blood. Flow cytometry analysis showed that the fre-
quency of CD4+PD-1+ cells, but not CD8+PD-1+ cells, was
increased in the PBMCs of PDAC patients (Fig. 5a,b); this is
consistent with the elevated PD-1 gene expression of CD4+
cells in PDAC patients shown using RTD-PCR (Fig. S2a, Data
S2). The frequency of regulatory T cells, phenotypically
defined as a CD4+CD25+CD127low/ population,(12) was
greater in the peripheral blood of PDAC patients (Fig. 5c);
however, FoxP3 gene expression was not significantly ele-
vated in CD4+ T cells of PDAC patients (Fig. S2b, Doc. S2).
The frequencies of CD4+PD-1+ T cells and
CD4+CD25+CD127low/ cells were not correlated (Fig. 5d).
Neither the frequency of CD4+PD-1+ T cells nor
CD4+CD25+CD127low/ T cells was associated with cancer
progression stages (Fig. 5e,f). However, patients whose
responsiveness to chemotherapy were progressive disease
tended to show a relatively high frequency of CD4+PD-1+
cells in the peripheral blood compared to patients with a
diagnosed therapeutic effect of stable disease or partial
responsiveness with chemotherapy, whereas this was not

























































































Fig. 2. Concentration of cytokines and chemokines in sera obtained from pancreatic ductal adenocarcinoma patients (n = 50) prior to treat-
ment and from healthy volunteers (n = 27). The serum concentration of cytokines and chemokines was measured using a multiplex bead immu-
noassay system. (a) Interleukin (IL)-6, (b) IL-7, (c) monocyte chemotactic protein-1, (d) IL-15, (e) interferon-c-inducible protein-1, and (f) IL-8.
*P < 0.05, **P < 0.01.
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Fig. 3. Unsupervised clustering analysis of gene expression profiles of subfractions of peripheral blood cells from patients with pancreatic duc-
tal adenocarcinoma (PK; n = 7) and healthy volunteers (n = 5). RNA was isolated from entire blood cells or each subfraction of peripheral blood
cells, followed by gene expression analysis using DNA microarray. Genes that passed the quality check control were used in each clustering analy-
sis. (a) Entire blood cells, 7039 genes; (b) CD14+ cells, 6602 genes; (c) CD4+ cells, 6770 genes; (d) CD8+ cells, 7621 genes; and (e) CD15+ cells, 9728
genes.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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Fig. 4. Unsupervised clustering analysis of the gene expression profile of CD14+ monocytes and CD4+ T cells in the peripheral blood of pancre-
atic ductal adenocarcinoma (PDAC) patients (PK) and healthy volunteers. RNA was isolated from all blood cells or each subfraction of peripheral
blood cells from 31 PDAC patients and 22 healthy volunteers, followed by gene expression analysis using DNA microarray. (a, b) Hierarchical
analysis of gene expression for isolated CD4+ cells in peripheral blood using all 10 868 filtered genes (a) or 266 genes whose expression was sig-
nificantly altered between PDAC patients and healthy volunteers ≥1.5-fold with P < 0.001 (b). (c, d) Hierarchical analysis of gene expression for
isolated CD14+ cells in peripheral blood using all 11 947 filtered genes (c) or 126 genes whose expression was significantly altered between PDAC
patients and healthy volunteers ≥1.5-fold at P < 0.01 (d).
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divided PDAC patients into two groups: one with ≥10%
CD4+PD-1+ T cells, and the other with <10% of such cells
in peripheral blood. The overall survival of the former group
was relatively shorter than that of the latter group. However,
the P-value (P = 0.111) indicated that statistical significance
was not attained. These data suggest that the subpopulation
of peripheral CD4+ T cells from PDAC patients contained
the important subfraction of activated and exhausted
CD4+PD-1+ T cells, which may influence the therapeutic
effect of chemotherapy.
Discussion
In the current study, we examined systemic inflammatory
conditions of PDAC by analyzing the PDAC tissues, sera,
and peripheral blood cells. We observed that the PDAC tis-
sues were remarkably infiltrated by monocytes ⁄macrophages
and CD4+ T cells, especially M2-phenotype macrophages and
PD-1+ cells. Serum concentrations of IL-6, IL-7, IL-15,
MCP-1, and IP-10 were elevated in PDAC patients, suggest-
ing humoral inflammatory mediators related to the macro-
phages and CD4+ T cells were present in the blood of PDAC
patients. In addition, we observed distinctively different gene
expression profiles of CD14+ monocytes and CD4+ T cells
among subfractions of peripheral blood cells between PDAC
patients and healthy volunteers. Cell cycle processes as well
as inflammation-associated biological processes were com-
monly related to upregulated genes in the CD14+ monocytes
and CD4+ T cells of PDAC patients. More intriguingly, PD-
1, an important molecule that is upregulated in activated T
cells and attenuates T cell receptor signaling, was upregulated
in the CD4+ T cells of PDAC patients. The frequency of
CD4+PD-1+ T cells was increased and correlated with a
resistance to chemotherapy.
Pathologically, PDAC tissues were substantially infiltrated
by monocytes ⁄macrophages and CD4+T cells. Monocytes
⁄macrophages are generally considered to be involved in non-
specific innate immunity; they digest antigens in the presence
of pro-inflammatory cytokines.(13) In the context of cancer
immunity, two important subsets of monocytes ⁄macrophages
have been recognized, M1 and M2 macrophages.(14) M1 mac-
rophages play a principal role in anticancer immunity, whereas
M2 macrophages sustain or promote cancer growth by inhibit-
ing anticancer immunity. We observed a substantial number of
CD163+ cells among CD33+ and neutrophil elastase-negative
macrophages, suggesting an M2 macrophage phenotype(15) in
PDAC tissues, which presumably contributes to sustained can-
cer growth.
Among infiltrated CD4+ T cells in PDAC tissues, the
expression of FoxP3 and PD-1 was frequently observed. FoxP3
is a transcriptional factor that is suggestive of activated T cells
as well as regulatory T cells.(16) PD-1 is a receptor, whose
expression is induced in activated T cells, attenuating the sig-
nal transduced from a T cell receptor encountered by a cognate
antigen.(17–19) These inflammatory features of PDAC tissues
highlight monocytes ⁄macrophages and CD4+ T cells, espe-
cially M2 macrophages and exhausted CD4+PD-1+ T cells,
which may contribute to cancer progression.
Previously, we observed that the gene expression profile of
total blood cells from patients with digestive cancers was
distinct from that of healthy volunteers.(11) This is consistent
with the current study, in which the gene expression profile of
CD14+ monocytes and CD4+ T cells in PBMCs as well as
entire blood populations was distinct between PDAC patients
and healthy volunteers. Affected genes, most of which were up-
regulated, were related to cell cycle and inflammation processes
in CD14+ monocytes and CD4+ T cells; this suggests that these
inflammatory cells in the peripheral blood were in an activated
Table 2. Biological process networks for 261 genes whose expression in CD14+ peripheral blood cells was significantly altered between




In data Network objects from active data
Blood coagulation 94 3.09E-06 4.33E-04 11 a-IIb ⁄ b-3 integrin, PAR1, thrombospondin 1, TFPI,
Galpha(q)-specific nucleotide-like GPCRs, P2Y1, ITGB3,
sCD40L, GP-IB beta, protein C, CD40L(TNFSF5)
Inflammation_NK cell cytotoxicity 164 1.32E-04 9.25E-03 12 KIR2DL4, KLRK1 (NKG2D), SAP, PPP2R2B, NKG2C, KIR3DL1,
IP3 receptor, NKG2A, histone H1, IgG1, CD94,
KLRC4 (NKG2F)
Inflammation_Interferon signaling 110 4.12E-04 1.92E-02 9 CCL5, PPAR-c, IFITM2, PKR, IFI17, IFI27, IFI6, IL-18R1, IFI44
Cell adhesion_Platelet-endothelium-
leucocyte interactions
174 3.05E-03 8.79E-02 10 CCL5, a-IIb ⁄ b-3 integrin, DNAM1, thrombospondin 1,
PDGF-B, 08p22 ⁄ MSR1(CD204), GP-IB b, protein C,
CD40L(TNFSF5), JAM3
Cell cycle_Mitosis 179 3.74E-03 0.087907 10 ASPM, MCAK, PKR, cyclin B, cyclin B2, survivin, securin,
CAP-G ⁄ G2, histone H1, AF15q14
Inflammation_Complement system 73 0.00376744 0.087907 6 C2, Factor H, C2b, C2a, Factor I, clusterin
Cell cycle_Core 115 0.00935692 0.172396 7 CAP-G, MCM6, cyclin B, cyclin B2, survivin, securin, CDK6
Cell cycle_G2–M 206 0.00985118 0.172396 10 Histone H1.5, p38 MAPK, CAP-G, cyclin B, PDGF-B,




223 0.01649253 0.256551 10 Ephrin-B receptors, ephrin-A receptors, Galpha(q)-specific
peptide GPCRs, EDNRB, thrombospondin 1, RhoB,
IP3 receptor, PKC, IL-18R1, clusterin
Cell cycle_S phase 149 0.03378318 0.438589 7 Histone H1.5, MCM6, cyclin B, cyclin B2, securin, histone
H1, ChAF1 subunit B
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Symbol Description Accession† Defined gene list
5.10E-06 1.666666667 DLC1 Deleted in liver cancer 1 NM_001164271
2.21E-05 2.083333333 HPGD Hydroxyprostaglandin
dehydrogenase 15-(NAD)
NM_000860




4.11E-05 1.612903226 DENND1B DENN ⁄ MADD domain
containing 1B
NM_001142795
4.23E-05 1.851851852 AMIGO2 Adhesion molecule with Ig-
like domain 2
NM_001143668
0.0000435 2.631578947 MSR1 Macrophage scavenger
receptor 1
NM_002445 Phagosome
8.58E-05 1.724137931 EPSTI1 Epithelial stromal
interaction 1 (breast)
NM_001002264
0.0000927 2.083333333 ARID5B AT rich interactive
domain 5B (MRF1-like)
NM_001244638
0.0001720 1.587301587 EIF2AK2 Eukaryotic translation
initiation factor
2-alpha kinase 2
NM_001135651 Bone remodelling, double-stranded RNA-induced
gene expression, inactivation of GSK3 by AKT
causes accumulation of b-catenin in alveolar
macrophages, regulation of EIF2, Toll-like receptor
pathway, hepatitis c, protein processing in
endoplasmic reticulum
0.0001827 1.666666667 FBXO38 F-box protein 38 NM_001271723




0.0002584 1.694915254 FKBP5 FK506 binding protein 5 NM_001145775




0.0003545 16.12903226 DDX3Y DEAD (Asp-Glu-Ala-Asp)
box polype
ptide 3, Y-linked
NM_001122665 RIG-I-like receptor signaling pathway
0.0004157 17.85714286 RPS4Y2 Ribosomal protein S4,
Y-linked 2
NM_001039567
4.29E-04 2.777777778 FAM20A Family with sequence
similarity 20, member A
NM_001243746
0.0004546 2.040816327 CLU Clusterin NM_001831
4.59E-04 17.54385965 RPS4Y1 Ribosomal protein S4,
Y-linked 1
NM_001008 Ribosome
5.09E-04 1.5625 VWCE Von Willebrand factor
C and EGF domains
NM_152718
5.50E-04 1.639344262 CDK6 Cyclin-dependent kinase 6 NM_001145306 Cell cycle: G1 ⁄ s checkpoint, cyclins and cell cycle
regulation, estrogen-responsive protein EFP
controls cell cycle and breast tumors growth,
influence of Ras and Rho proteins on G1 to S
transition, cell cycle, chronic myeloid leukemia,
glioma, melanoma, non-small-cell lung cancer,
p53 signaling pathway, pancreatic cancer,
pathways in cancer, small-cell lung cancer
5.57E-04 1.612903226 P2RY1 Purinergic receptor P2Y,
G-protein coupled, 1
NM_002563 Neuroactive ligand–receptor interaction
0.0005792 2.083333333 PRDM1 PR domain containing 1,
with ZNF domain
NM_001198
0.0005939 1.785714286 IFI44 Interferon-induced
protein 44
NM_006417
6.98E-04 1.515151515 MT2A Metallothionein 2A NM_005953
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Symbol Description Accession† Defined gene list
0.0007509 1.694915254 LY6E Lymphocyte antigen 6
complex, locus E
NM_001127213




0.0008473 1.754385965 C2 Complement component 2 NM_000063 Classical complement pathway, complement pathway,
lectin-induced complement pathway, complement
and coagulation cascades, Staphylococcus aureus
infection, systemic lupus erythematosus




1.27E-03 1.851851852 NGFRAP1 Nerve growth factor
receptor (TNFRSF16)
associated protein 1
NM_014380 Neurotrophin signaling pathway
0.0013756 2.222222222 PDK4 Pyruvate dehydrogenase
kinase, isozyme 4
NM_002612
1.52E-03 2.564102564 ZFY Zinc finger protein, Y-linked NM_001145275
1.64E-03 1.515151515 CABLES1 Cdk5 and Abl enzyme
substrate 1
NM_001100619
1.68E-03 1.694915254 TNIK TRAF2 and NCK
interacting kinase
NM_001161560
0.0018725 1.538461538 CHAF1B Chromatin assembly
factor 1, subunit B (p60)
NM_005441 BTG family proteins and cell cycle regulation
0.0018950 1.724137931 BTG3 BTG family, member 3 NM_001130914 RNA degradation
0.0019480 1.612903226 HDGFRP3 Hepatoma-derived growth
factor, related protein 3
NM_016073
2.08E-03 2.631578947 PPARG Peroxisome proliferator-
activated
receptor gamma
NM_005037 Basic mechanism of action of PPARa, PPARb(d) and
PPARg and effects on gene expression, nuclear
receptors in lipid metabolism and toxicity, role of
PPAR-c coactivators in obesity and thermogenesis,
visceral fat deposits and the metabolic syndrome,
Huntington’s disease, osteoclast differentiation,
pathways in cancer, PPAR signaling pathway,
thyroid cancer








0.0023519 1.5625 FOXC1 Forkhead box C1 NM_001453
2.36E-03 1.587301587 PLAC8 Placenta-specific 8 NM_001130715
2.41E-03 1.666666667 BEX1 Brain expressed, X-linked 1 NM_018476
0.0024547 1.515151515 PIM1 Pim-1 oncogene NM_001243186 Acute myeloid leukemia, Jak-Stat signaling pathway
0.0024567 2.173913043 CST7 Cystatin F (leukocystatin) NM_003650
0.0025775 1.960784314 PCSK6 Proprotein convertase
subtilisin ⁄ kexin type 6
NM_002570
0.0029609 1.639344262 REST RE1-silencing transcription
factor
NM_001193508 Huntington’s disease
0.0029864 1.666666667 FKBP11 FK506 binding protein
11, 19 kda
NM_001143781
0.0029868 1.639344262 OASL 20-50-oligoadenylate
synthetase-like
NM_001261825
0.0033994 1.754385965 CD226 CD226 molecule NM_006566 Cell adhesion molecules
3.85E-03 1.538461538 PNMA1 Paraneoplastic
Ma antigen 1
NM_006029
PK, pancreatic cancer patients.
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state. Significantly affected genes in CD14+ monocytes were
also related to blood coagulation, cell adhesion, and the devel-
opmental regulation of angiogenesis, all of which are important
biological processes of activated macrophages. However, it
remains to be elucidated whether the immunological conse-
quence of activation of monocytes ⁄macrophages in peripheral
blood cells anti-cancer or cancer promoting effect inhibits or
promotes cancer development.
Affected genes in CD4+ T cells were also related to DNA
damage and apoptosis. CD4+ T cells undergo activation-
induced cell death through Fas-mediated signaling,(20) and
Fas (CD95) was among the most upregulated genes. Taken
together, gene expression analysis disclosed that myeloid-
lineage CD14+ monocytes ⁄macrophages and CD4+ T cells
are important affected fractions of immune-mediating cells
in the peripheral blood cells of PDAC patients, with the
implication of a cancer-associated activated inflammatory
condition.
Corresponding to the upregulated expression of the PD-1
gene in the peripheral CD4+T cells of PDAC patients, the
frequency of CD4+PD-1+ cells in the peripheral blood of
PDAC patients was also increased. Intriguingly, the relatively
poor success of chemotherapy correlated with an increased
level of CD4+PD-1+ T cells. The overall survival of PDAC
patients with ≥10% CD4+PD-1+ T cells was somewhat
shorter than that of those with <10% such cells, although
statistical significance was not attained. Any underlying role
for CD4+PD-1+ T cells in terms of responsiveness to chemo-
therapy remains to be explored; we observed neither a sup-
porting effect on cancer cell proliferation nor a suppressive
effect on IFN-c-secreting activated cytotoxic T cells in vitro
(data not shown). PD-1 attenuates T cell receptor signaling,
therefore, CD4+ T cells expressing PD-1 are considered to
be exhausted if anticancer inflammation is not induced. An
increased level of CD4+PD-1+T cells may reflect the fact
that the anticancer inflammation induced during chemother-
apy is inadequate. Clinical trials featuring blocking of PD-1-
expressing cells (using an anti-PD-1 antibody) to enhance
anticancer immune reactions are currently underway; this
may be a valuable therapy for lung cancer and melanoma,
overcoming immune resistance.(21) Although further clinical
studies are needed to explore the role played by CD4+PD-1+
T cells in chemotherapy and overall survival, our current
finding that CD4+ PD-1+ T cells infiltrate PDAC tissues and
increase in proportion among peripheral blood cells suggests
that immunotherapy targeting the exhausted PD-1+ popula-
tion may be a useful novel immunotherapeutic approach
toward PDAC.
Table 4. Biological process networks for 496 genes whose expression in CD4+ peripheral blood cells was significantly altered. between




In data Network objects from active data
Cell cycle_G2–M 206 6.19E-08 9.48E-06 26 Histone H1.5, INCENP, BUB1, lamin B, UBE2C, cyclin A2,
CAP-G, ETS2, GADD45 a, CAP-C, Ceb1, cyclin A, CAP-G ⁄ G2,
Chk1, PLK1, KNSL1, HDAC4, MAPKAPK2, cyclin B, cyclin
B2, securin, lamin B1, histone H1, GADD45 b, 14-3-3,
14-3-3 eta
Cell cycle_S phase 149 1.87E-07 1.43E-05 21 Histone H1.5, BUB1, Cdt1, AHR, PCNA, cyclin A2, CDC18L
(CDC6), CDH1, geminin, GADD45 a, cyclin A, PLK1, E2F1,
cyclin B, cyclin B2, TEP1, separase, securin, DOC-1, histone
H1, GADD45 b
Cell cycle_Mitosis 179 1.07E-06 5.45E-05 22 INCENP, BUB1, MCAK, PKR, CAP-C, cyclin A, CAP-G ⁄ G2,
PLK1, KNSL1, ASPM, PBK, HZwint-1, tubulin a, cyclin B,
cyclin B2, separase, survivin, securin, a-centractin,
histone H1, AF15q14, 14-3-3 eta
Cell cycle_Core 115 1.44E-06 5.52E-05 17 INCENP, BUB1, Cdt1, CDC18L (CDC6), CAP-G, CDH1, CAP-C,
cyclin A, PLK1, E2F1, p19, cyclin B, E2F2, cyclin B2,
separase, survivin, securin
Apoptosis_Apoptotic nucleus 159 3.27E-05 0.000999 18 histone H1.5, AHR, lamin B, PKR, Bcl-6, HMG2, GADD45 a,
Chk1, E2F1, tBid, ELMO2, tubulin a, separase, lamin B1,
histone H1, Bid, GADD45 b, clusterin
Cell cycle_G1–S 163 0.000152 0.003865 17 BCAT1, BTG3, PCNA, cyclin A2, CDH1, ETS2, GADD45 a,
TYSY, Ceb1, cyclin A, Chk1, PLK1, E2F1, p19, GADD45 b,
14-3-3, 14-3-3 eta
Cytoskeleton_Spindle microtubules 109 0.000245 0.004556 13 INCENP, BUB1, MCAK, UBE2C, sororin, PLK1, KNSL1, HZwint-1,
tubulin a, cyclin B, cyclin B2, separase, securin
DNA damage_Checkpoint 124 0.000254 0.004556 14 PCNA, cyclin A2, heme oxygenase 1, GADD45 a, cyclin A,
Chk1, E2F1, cyclin B, cyclin B2, separase, securin,
GADD45 b, 14-3-3, 14-3-3 eta
Inflammation_Interferon signaling 110 0.000268 0.004556 13 PKR, IFNGR1, IFI6, MxA, IFN-a, IL-18R1, IFI27, TIMP1,
FasR(CD95), PML, IFI44, ISG15, SERPINB9
Apoptosis_Apoptotic mitochondria 77 0.002527 0.038666 9 NIP2, RIPK2, PUMA, Bax, tBid, Bid, endophilin B1, 14-3-3,
14-3-3 eta
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Symbol Description Accession no. Defined gene list
3.00E-07 1.612903226 LPP LIM domain containing preferred
translocation partner in lipoma
NM_001167671
3.00E-07 1.754385965 PTTG1 Pituitary tumor-transforming 1 NM_004219 Cell cycle, oocyte meiosis
4.00E-07 2.040816327 PRDM1 PR domain containing 1, with
ZNF domain
NM_001198
4.00E-07 1.666666667 GMNN Geminin, DNA replication inhibitor NM_001251989
5.00E-07 1.754385965 EIF2AK2 Eukaryotic translation initiation
factor 2-alpha kinase 2
NM_001135651 Bone remodelling, double-stranded RNA-
induced gene expression, inactivation of
Gsk3 by AKT causes accumulation of
b-catenin in alveolar macrophages,
regulation of eIF2, Toll-Like receptor
pathway, hepatitis C, protein processing in
endoplasmic reticulum
2.20E-06 1.5625 PAK2 p21 protein (Cdc42 ⁄ Rac)-
activated kinase 2
NM_002577 Agrin in postsynaptic differentiation, FAS
signaling pathway (CD95), Fc epsilon
receptor I signaling in mast cells, HIV-I Nef:
negative effector of Fas and TNF,
MAPKinase signaling pathway, TNFR1
signaling pathway, axon guidance, ErbB
signaling pathway, focal adhesion, MAPK
signaling pathway, regulation of actin
cytoskeleton, renal cell carcinoma, T cell
receptor signaling pathway
2.50E-06 1.851851852 EPSTI1 Epithelial stromal interaction
1 (breast)
NM_001002264
2.70E-06 2 CASC5 Cancer susceptibility candidate 5 NM_144508
2.90E-06 1.694915254 SLA Src-like-adaptor NM_001045556
3.00E-06 1.694915254 SAR1A SAR1 homolog A (S. cerevisiae) NM_001142648 Protein processing in endoplasmic reticulum
3.00E-06 1.538461538 PML Promyelocytic leukemia NM_002675 Regulation of transcriptional activity by
PML, acute myeloid leukemia, endocytosis,
pathways in cancer, ubiquitin-mediated
proteolysis
3.20E-06 1.639344262 MT1E Metallothionein 1E NM_175617
3.90E-06 1.492537313 LOC442157 Heterogeneous nuclear
ribonucleoprotein L pseudogene
4.30E-06 1.666666667 BAX BCL2-associated X protein NM_004324 Apoptotic signaling in response to DNA
damage, ceramide signaling pathway,
hypoxia and p53 in the cardiovascular
system, p53 signaling pathway, regulation
of BAD phosphorylation, role of
mitochondria in apoptotic signaling,
amyotrophic lateral sclerosis, apoptosis,
colorectal cancer, Huntington’s disease,
neurotrophin signaling pathway, p53
signaling pathway, pathways in cancer,
Prion diseases, protein processing in
endoplasmic reticulum
4.70E-06 1.5625 PTPRC Protein tyrosine phosphatase,
receptor type, C
NM_001267798 Activation of Csk by cAMP-dependent
protein kinase inhibits signaling through
the T cell receptor, B lymphocyte cell
surface molecules, Lck and Fyn tyrosine
kinases in initiation of TCR activation, T
cytotoxic cell surface molecules, T helper
cell surface molecules, cell adhesion
molecules, Fc cR-mediated phagocytosis,
primary immunodeficiency, T cell receptor
signaling pathway
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Symbol Description Accession no. Defined gene list
4.80E-06 1.5625 MUC1 Mucin 1, cell surface
associated
NM_001018016
5.40E-06 1.5625 MT1X Metallothionein 1X NM_005952
5.70E-06 1.666666667 HPGD Hydroxyprostaglandin
dehydrogenase 15-(NAD)
NM_000860
6.00E-06 2 CENPN Centromere protein N NM_001100624
6.00E-06 1.538461538 POMP Proteasome maturation
protein
NM_015932 Proteasome
6.10E-06 1.612903226 FZR1 Fizzy ⁄ cell division cycle 20
related 1 (Drosophila)
NM_001136197 Cell cycle, progesterone-mediated oocyte
maturation, ubiquitin-mediated proteolysis
6.20E-06 1.612903226 HMGB2 High mobility group box 2 NM_001130688 Apoptotic DNA fragmentation and tissue
homeostasis, granzyme A-mediated
apoptosis pathway




7.50E-06 2.127659574 CPT1A Carnitine palmitoyl-
transferase 1A (liver)
NM_001031847 Mitochondrial carnitine palmitoyltransferase
system, reversal of insulin resistance by leptin,
adipocytokine signaling pathway, fatty
acid metabolism, PPAR signaling pathway
7.60E-06 2.083333333 UBE2C Ubiquitin-conjugating
enzyme E2C
NM_007019 Ubiquitin-mediated proteolysis
8.40E-06 2.272727273 TK1 Thymidine kinase 1, soluble NM_003258 Drug metabolism – other enzymes, metabolic
pathways, pyrimidine metabolism




8.70E-06 1.538461538 MT1H Metallothionein 1H NM_005951




1.02E-05 1.538461538 DNAJC3 Dnaj (Hsp40) homolog,
subfamily C, member 3
NM_006260 Double-stranded RNA-induced gene expression,
protein processing in endoplasmic reticulum
1.05E-05 1.587301587 MT1L Metallothionein 1L (gene ⁄
pseudogene)
NR_001447
1.08E-05 1.5625 ACTR2 ARP2 actin-related protein
2 homolog (yeast)
NM_001005386




1.11E-05 2.325581395 KIAA0101 KIAA0101 NM_001029989
1.19E-05 26.31578947 DDX3Y DEAD (Asp-Glu-Ala-Asp) box
polypeptide 3, Y-linked
NM_001122665 RIG-I-like receptor signaling pathway
1.20E-05 1.785714286 CDCA8 Cell division cycle associated 8 NM_001256875
1.25E-05 1.612903226 DDB2 Damage-specific DNA binding
protein 2, 48kda
NM_000107 Nucleotide excision repair, p53 signaling
pathway, ubiquitin-mediated proteolysis
1.29E-05 1.754385965 ALCAM Activated leukocyte
cell adhesion
molecule
NM_001243280 Cell adhesion molecules
1.31E-05 1.515151515 RNF11 Ring finger protein 11 NM_014372
1.33E-05 1.515151515 CCNK Cyclin K NM_001099402
1.33E-05 1.470588235 REEP3 Receptor accessory protein 3 NM_001001330
1.35E-05 2.127659574 MT1M Metallothionein 1M NM_176870
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Concentrations of the macrophage- and T cell-related cyto-
kines and chemokines IL-6, IL-7, IL-15, MCP-1, and IP-10
were significantly elevated in the sera of PDAC patients. Inter-
leukin-15, MCP-1, and IP-10 are produced by monocytes ⁄mac-
rophages, considerably inducing or activating an innate
immune reaction.(22–24) The biological function of the cytokine
IL-7 is maintenance of the na€ıve T cells as well as T cell pro-
liferation,(25) whereas IL-6 is involved in macrophage polariza-
tion and in the initiation and proliferation of PDAC.(9)
Although elevation of these cytokines ⁄ chemokines is consid-
ered to reflect the inflammatory condition of PDAC, the clini-
cal impact of the elevated serum cytokines and chemokines in
PDAC should be further studied in the context of anticancer or
cancer-promoting humoral immune reactions.
Although the current study highlighted the importance of
focusing on monocytes ⁄macrophages and CD4+ T cells in
local PDAC tissues as well as peripheral blood, these immune-
mediating populations are heterogeneous and extremely com-
plex. The increased frequency of CD4+PD-1+ T cells, which
are presumably an important population affecting host
immunity against cancer, suggest that significant subfractions
in monocytes ⁄macrophages and the CD4+ T cell population
may exist. Additional detailed studies are needed to identify
which subfractions are significantly associated with the clinical
prognosis of PDAC patients and to verify the clinical impact
of the subfractions in well-designed clinical trials.
In conclusion, the current study showed that PDAC is asso-
ciated with a systemic inflammatory condition, highlighting
the presence of activated monocytes ⁄macrophages and CD4+
T cells, which are presumed to be exhausted both in local can-
cer tissues and peripheral blood. Substantial infiltration of can-
cer-promoting immune cells, including M2 macrophages, in
local cancer tissues was concomitant with the increased
expression of PD-1 in T cells as well as the increased fre-
quency of CD4+PD-1+ T cells in the peripheral blood of
PDAC patients. This may contribute, in part, to persistent
chronic inflammation as a consequence of failure to eliminate
cancer despite the host immune response. However, the
immune system includes both cancer-promoting immune-medi-
ating cells and anticancer inflammatory cells. Further studies
focusing on monocyte ⁄macrophage and CD4+ T cell subfrac-
tions in PDAC patients may reveal further details regarding
the PDAC immune condition, and such information may be
helpful in the development of novel diagnostic markers for
detecting PDAC. It may also provide meaningful insights into
the development of novel immunological therapeutic
approaches for modulating the inflammatory condition in





Symbol Description Accession no. Defined gene list
1.54E-05 1.666666667 FAS Fas (TNF receptor
superfamily, member 6)
NM_000043 Antigen-dependent B cell activation,
bystander B cell activation, CTL-mediated
immune response against target cells, FAS
signaling pathway (CD95), HIV-induced T
cell apoptosis, HIV-I Nef: negative effector
of Fas and TNF, IL-2 receptor b chain in
T cell activation, keratinocyte
differentiation, regulation of
transcriptional activity by PML, stress
induction of HSP regulation, African
trypanosomiasis, allograft rejection,
Alzheimer’s disease, apoptosis,
autoimmune thyroid disease, Chagas
disease (American trypanosomiasis),
cytokine–cytokine receptor interaction,
graft-versus-host disease, MAPK signaling
pathway, natural killer cell-mediated
cytotoxicity, p53 signaling pathway,
pathways in cancer, type I diabetes mellitus
1.55E-05 1.724137931 HERPUD1 Homocysteine-inducible, endoplasmic
reticulum stress-inducible, ubiquitin-
like domain member 1
NM_001010989 Protein processing in endoplasmic reticulum
1.58E-05 1.666666667 LPGAT1 Lysophosphatidylglycerol
acyltransferase 1
NM_014873 Glycerophospholipid metabolism
1.67E-05 1.612903226 FKBP5 FK506 binding protein 5 NM_001145775
1.71E-05 1.886792453 PDCD1 Programmed cell death 1 NM_005018 Cell adhesion molecules, T cell receptor
signaling pathway
1.76E-05 37.03703704 RPS4Y2 Ribosomal protein S4, Y-linked 2 NM_001039567
1.79E-05 2.325581395 BIRC5 Baculoviral IAP repeat containing 5 NM_001012270 B cell survival pathway, colorectal cancer,
pathways in cancer
1.79E-05 2.040816327 CDCA2 Cell division cycle associated 2 NM_152562
PK, pancreatic cancer patients.
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Fig. 5. Frequency of CD4+PD-1+ cells and CD4+CD25+CD127low/ cells in PBMCs of pancreatic ductal adenocarcinoma (PDAC) patients (n = 50)
and healthy volunteers (n = 27). The frequencies of CD4+PD-1+ cells (a), CD8+PD-1+ cells (b), and CD4+CD25+CD127low/ cells (c) were assessed by
flow cytometry. (d) Scattergram of the frequencies of CD4+PD-1+ cells and CD4+CD25+CD127low/ cells in PDAC patients. (e, f) The frequency of
CD4+PD-1+ cells (e) and CD4+CD25+CD127low/ cells (f) in the PBMCs of PDAC patients in the context of each clinical stage. (g, h) The chemother-
apy responsiveness and frequency of CD4+PD-1+ cells (g) and CD4+CD25+CD127low/ cells (h). PD, progressive disease; PR, partial responsiveness;
SD, stable disease. *P < 0.05; **P < 0.01.
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